BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14599084)

  • 21. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
    Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
    Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
    Nicholas MK; Lukas RV; Jafri NF; Faoro L; Salgia R
    Clin Cancer Res; 2006 Dec; 12(24):7261-70. PubMed ID: 17189397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypeptide growth factors and attachment proteins in periodontal wound healing and regeneration.
    Caffesse RG; Quiñones CR
    Periodontol 2000; 1993 Feb; 1(1):69-79. PubMed ID: 8401862
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.
    Favoni RE; de Cupis A
    Pharmacol Rev; 2000 Jun; 52(2):179-206. PubMed ID: 10835099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Breast cancer and polypeptide growth factors].
    Rømer J; Holst-Hansen C; Moser C; Brünner N
    Nord Med; 1992; 107(2):49-52. PubMed ID: 1538961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide growth factors and wound healing.
    McGrath MH
    Clin Plast Surg; 1990 Jul; 17(3):421-32. PubMed ID: 2199134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms for oncogenic activation of the epidermal growth factor receptor.
    Zandi R; Larsen AB; Andersen P; Stockhausen MT; Poulsen HS
    Cell Signal; 2007 Oct; 19(10):2013-23. PubMed ID: 17681753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibitors in children with malignant gliomas.
    Herrington B; Kieran MW
    Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting malignant glioma survival signalling to improve clinical outcomes.
    Wong ML; Kaye AH; Hovens CM
    J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Hägerstrand D; Hesselager G; Achterberg S; Wickenberg Bolin U; Kowanetz M; Kastemar M; Heldin CH; Isaksson A; Nistér M; Ostman A
    Oncogene; 2006 Aug; 25(35):4913-22. PubMed ID: 16547494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autocrine and paracrine regulation of kidney epithelial cell growth.
    Mendley SR; Toback FG
    Annu Rev Physiol; 1989; 51():33-50. PubMed ID: 2653186
    [No Abstract]   [Full Text] [Related]  

  • 39. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors.
    Ma D; Nutt CL; Shanehsaz P; Peng X; Louis DN; Kaetzel DM
    Cancer Res; 2005 Jul; 65(13):5523-34. PubMed ID: 15994924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy.
    Henson ES; Gibson SB
    Cell Signal; 2006 Dec; 18(12):2089-97. PubMed ID: 16815674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.